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Abstract
Objective
To describe the pain decrease considered as clinically relevant when designing a trial and reporting its results.
Methods
A systematic review of the literature in MEDLINE was conducted to select randomised controlled trials (RCTs) with pain as a
primary outcome. Data extracted included the definition (terms and values) of a clinically relevant difference in pain, the type of pain
studied (acute or chronic), the level of application (group or individual) of the clinically relevant difference, and the reference
justifying the choice of value for clinically relevant difference.
Study Design and Setting
74 trials were included and only 16 articles justified the choice of a value for clinically relevant difference with a reference citation.
The values chosen for the clinically relevant relative decrease in pain varied from 4 to 40 mm or 15  to 55  at the group level and% %
from 20 to 50 mm at the individual level. In 7 articles, the authors confused the application of the reference value at the individual or
group level.
Conclusion
Our review revealed a great heterogeneity in definition, format and values of what is considered a clinically relevant difference in
pain in RCTs of analgesics and standardisations are advisable.
MESH Keywords Analgesics ; administration & dosage ; Humans ; Pain ; classification ; drug therapy ; psychology ; Pain Measurement ; standards ; Randomized
Controlled Trials as Topic ; Reference Standards
Author Keywords Clinical trials ; clinically relevant ; pain measurement ; data interpretation ; treatment outcome ; group or patient perspective
Pain is a subjective experience, and the wide variation in the experience of pain leads to large variability in ratings of pain by patients
undergoing similar interventions . Several scales have been developed to assess pain intensity in daily practice and in randomised[1 ]
controlled trials (RCTs) assessing analgesic therapies. The most widely used scales are the visual analog scale (VAS) and the numeric
rating scale (NRS), both of which are sensitive to change .[2 ]
The reporting of a sample size calculation for an RCT has been recommended since the 1990s . At the group level, this calculation[3 ]
relies on demonstrating a clinically relevant difference between groups, if it exists. This clinically relevant difference is used to calculate
the sample size and to interpret the RCT results. The choice of the value of this clinically relevant difference is an important part when
designing a trial: a large clinically relevant difference will lead to a small sample size but increases the risk of negative results. At the
opposite end, a small clinically relevant difference will lead to a very large sample size, is more likely to obtain positive results but this
small clinically relevant difference may be not pertinent for a clinician. Much literature addresses what is considered a clinically relevant
difference for a patient-reported outcome. The minimal clinically important difference (MCID) is defined as the smallest difference in“
score in the domain of interest which patients perceive as beneficial and which would mandate, in absence of troublesome side effects and
excessive cost, a change in patients  management  . However, definitions of the MCID differ widely. Beaton has proposed a’ ” [4 ]
classification of responsiveness in terms of three features or axes . At the individual level, the clinically relevant difference in pain can[5 ]
be assessed by the patient acceptable symptom state (PASS), the highest level of pain beyond which patients consider themselves well [6 –
.8 ]
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When analysing the results from trials, comparing continuous data between groups to obtain the absolute mean change in pain
intensity offers great statistical power ,  but is not meaningful for everyone . Presenting results as a percentage of responders[9 10 ] [11 ]
after defining a threshold of improvement (MCID) or the threshold of acceptable pain (PASS) at the individual level enhances the
relevance of the results .[12 ]
Two international working groups, the IMMPACT  and the OMERACT  developed guidelines in reporting results of[13 –15 ] [16 ]
RCT assessing chronic pain and recommended presenting both at the group level with differences in means and at the individual level with
proportion of responders.
To investigate these issues in pain assessment, the aim of our study was to review reports of RCTs investigating analgesics for pain to
study the difference in pain outcome that trialists have considered clinically relevant when designing such RCTs and reporting results.
Methods
Study design
This study was a systematic review of reports of RCTs assessing analgesics for pain.
Report selection process
A search was conducted using MEDLINE (via PUBMED) to retrieve all reports published from February 19, 2005, to February 19,
2007, of clinical trials with pain as the primary outcome. We used the key word pain  with limits of all adults: 19 years , Randomized“ ” “ + ” “
Controlled Trial , Humans , and Core clinical journals . The core clinical journal selection limited the search to the 120 journals of” “ ” “ ”
immediate interests included in the Abridged Index Medicus (AIM) from MEDLINE.
One of the authors (ARW) read titles and abstracts of retrieved articles. Inclusion criteria were superiority RCTs with 2 parallel arms
and pain measured with a VAS or a NRS as the primary outcome. Exclusion criteria were all designs other than 2 parallel arms (such as
cross-over design or 3 or more arms), animal studies, paediatric studies, phase I or II trials, or non-therapeutic trials (e.g., metrologic
studies and epidemiologic studies).
Definitions
For practical reasons, to avoid confusion between terms, the clinically relevant difference is termed  in this paper. In analysedΔ
response to treatment,  was described according to the three axes of Beaton s cube : the first axis is the setting, or the individual orΔ ’ [5 ]
group level. Two types of response occur at the individual level: an improvement of more than the  or an improvement that leads theΔ
patient beyond an acceptable threshold of pain. The second axis is which scores are contrasted: the difference between , or absolute“ ”
difference, is the difference between groups, expressed as the difference in means at the end of the study; the change within  is the relative“ ”
change within a group during the study, expressed as a mean (difference between endpoint and baseline within the group) or percentage
(percentage of improvement from baseline within the group); the difference between changes within  is the difference in improvement“ ”
between groups at the end of the study, expressed as a mean (difference of improvement in means) or percentage (difference of percentage
improvement). Finally, the third axis is the type of change (e.g., minimum change actually detectable beyond the error versus minimal
clinically important change).
Data extraction
A standardized data collection form was generated on the basis of a review of the literature and finalized by the research team. Before
beginning data extraction, one member of the team (AWR) tested the standardized form on a sample of 10 articles from 10 different
journals retrieved by the literature search and included in the final sample. Another member of the team reviewed the same articles to
discuss difficulties. The same reviewer (AWR) independently completed all the data extraction. The following data were recorded: general
information about the trial (i.e. year of publication, pathology, type of pain, aim of the trial ), sample size calculation with value and unit…
of measurement (millimetre or percentage) of , the term used for the  and how  was applied (individual or group level), including theΔ Δ Δ
axis of the  according to Beaton s cube . The expected baseline level of pain in each group was collected from the sample sizeΔ ’ [5 ]
calculation. If the expected baseline was not available, the final baseline level of pain in the control group or the control group level of pain
during the study was collected.
Data analysis
A descriptive analysis of the data extracted from the reports of the RCTs was performed, then assessed whether sample size
calculation was reported. The value chosen as the  in each trial was described in terms of medical area, type of control group (placebo orΔ
other analgesic intervention) and pain type (acute or chronic). The data for values expressed as continuous data (i.e., in millimetres) and as
percentages were analysed separately. The values of the  were compared to the expected baseline level of pain or if not available, to theΔ
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final control group baseline pain or to the control group level of pain during the study. At the group level, all values of the  wereΔ
represented in a graphic plotting the values of the  and the (expected) baseline pain, separating values given in means or in percentages.Δ
The use of the  in the report was then analysed according to Beaton s cube . The setting,  meaning individual or groupΔ ’ [5 ] “ ”
perspective, of the  was described. If a reference was cited to justify the choice of the  value, the reference was reviewed and theΔ Δ
appropriateness of the level for  used in the report and in the reference was noted. For RCTs assessing chronic pain, we assessed whetherΔ
the presentation of results followed the recommendations of IMMPACT  and OMERACT  in terms of presenting results both[13 –15 ] [16 ]
at the group level with differences in means and at the individual level with proportion of responders. Whether the scores being contrasted
were the same in the sample size calculation and results section was investigated. Finally, the type of change or difference was described:
the terms used to define  (e.g., minimum Clinically Relevant Difference, Minimum important difference). If a reference was cited toΔ
justify the choice of the , the reference was reviewed and the appropriateness of the term and its meaning in the report were noted.Δ
Results
Of the 603 articles retrieved from the MEDLINE search, the selection process lead to include 74 reports of RCTs ( ).figure 1 
Characteristics of the trials are summarized in . The trials were in the field of anaesthesiology or emergency medicine (n 28),Table 1 =
rheumatic diseases (n 19), neurology (n 5), gynaecology or obstetrics (n 9) or surgery (n 13).= = = =
A sample size calculation was reported in 59 articles (80 ), but in 47, data required for replicating the sample size calculation were%
incomplete or missing.
Of the 74 reports, 31 (42 ) defined the  by use of a specific term either in the sample size calculation or the discussion section.% Δ
Among these, 2 did not report the cut-off value used. Only 12 reports (20 ) reported in the sample size calculation the expected baseline%
pain before starting the experimental treatment.
For reports that described absolute difference at the group level, the values used for defining the  varied from 4 to 40 mm for acuteΔ
pain and from 10 to 20 mm for chronic pain. When addressing differences as percentage change, the  varied from 15  to 30  for acuteΔ % %
pain and from 30  to 55  for chronic pain. At the individual level, the threshold for improvement ranged from 20 to 50 mm for absolute% %
change and from 20  to 50  for percentage change. The threshold of pain above which a patient considered painful  ranged from 2 to 40% % “ ”
mm. No influence of the baseline control group expected or reported pain on the value of the  was observed in this study ( ).Δ figure 2 
The choice of the value of the delta either expressed on absolute change in mean or difference in percentage change did not depend on
the type of pain (acute or chronic, data not shown).. No trend for the choice of the value of the delta was identified depending on the
medical area of the RCT (for example, no difference between RCT assessing post-surgery pain and neuropathic pain RCT).
In terms of the first axis of Beaton s cube, the individual or group perspective, 17 reports (23 ) described pain results at the individual’ %
level and 46 (57 ) at the group level; in 15 (20 ), results were for both levels. For sample size calculation, the  was defined at the% % Δ
individual level more often in rheumatologic trials (42 ) than in trials of other medical areas (9 ; p 0.01). Only 8 articles investigating% % =
chronic pain (30 ) gave comparisons both in means and proportion of responders in the results section as recommended by IMMPACT%
and OMERACT. Only 16 reports (22 ) justified the choice of the  used in the sample size calculation by citing a reference; in 7 of these,% Δ
the cut-off value was used inappropriately ( ) and for inappropriate levels. For example, in one report  a 25  to 30  reductiontable 2 [17 ] % %
in pain from baseline was expected in the experimental group; to justify such a cut-off, the authors cited a reference  in which the[18 ]
threshold of 30  was defined as a clinical improvement at the individual level.%
In terms of the second axis of Beaton s cube, which scores were being contrasted, for sample size calculation, the  in 30 reports was a’ Δ
difference between , or an absolute difference in means between groups; in 12, a change within , or a relative change in means or“ ” “ ”
percentage; in 9, a difference between changes within ; and in 3, was represented by several axes. For the results section, in 62 reports, the“ ”
 was a difference between ; in 8, a change within ; in 12, a difference between changes within ; and in 10, was represented by severalΔ “ ” “ ” “ ”
axes. In 19 reports (35 ), the axis chosen for the  in the sample size calculation was not the same as that for the results section. For% Δ
example, in 6 reports, the authors chose as the  a difference of percentage improvement, for the sample size calculation and a differenceΔ
in means between groups for reporting the results.
In terms of the third axis of Beaton s cube, the type of change or difference, the terms used to define the  and the corresponding’ Δ
values are in . Eighteen different terms were used. Moreover, a given term could correspond to different definitions and to differenttable 3 
values. For instance, MCID was defined as a 20mm threshold for improvement of change from baseline at the patient level  but also as[19 ]
17.5 mm mean difference between groups . Confusion of concepts behind the choice of a term was noted. For instance, for sample size[20 ]
calculation, one author  used the value of 20 mm as a meaningful difference between groups and justified such a cut-off with a[21 ]
reference  that defined the value of 20 mm as the threshold of imprecision at the individual level ( ).[22 ] table 2 
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Discussion
This systematic literature review of reports of RCTs investigating analgesics for pain showed great heterogeneity in the definition of
what constitutes a clinically relevant difference in pain and confusion in these definitions that may be misleading in interpreting results.
There was a large variation of values used as the  in measuring pain, this variation was neither explained by the baseline pain, nor theΔ
type of pain, nor the medical area. The systematic review identified 18 different terms to define the . A same term was applied at theΔ
group or individual level and the same term could correspond to different values. Consequently, in 7 of 16 reports that justified a value by
a reference citation, the trial conclusions were not appropriate because of confusion in application of the value at the group or individual
level. In analysing the use of the  according to Beaton s cube axes, in 35  of articles, the axis chosen for the  in the sample sizeΔ ’ % Δ
calculation was not the same as that used to describe the results.
To our knowledge, this is the first study addressing the use and misuse of the  in RCTs assessing analgesics for pain. Many reportsΔ
have tried to define a value for the MCID for pain in specific medical conditions, but consensus is lacking on the value to use. Indeed, the
systematic review identified a large range of values used for the  both at the individual and group levels.Δ
One important result of this study is that only half of the selected articles reported a sample size calculation while the CONSORT
statement  had recommended since 1996 to include the sample size calculation in all reports of RCT.[3 ]
To enhance the relevance of the evaluation of pain in RCTs, the IMMPACT developed guidelines for assessment of chronic pain in
RCTs  and recommended presenting both absolute changes in pain intensity and proportion of patients showing decrease in pain[13 –15 ]
intensity of at least 30  from baseline. The OMERACT group, an international working group interested in outcome measurements in%
rheumatology, defined a threshold for reporting the results of change in pain level at the individual level for RCTs  As well, the draft[16 ]
document of the US Food and Drug Administration recommended giving results in means and proportions of responders. We found only 8
reports presenting results in terms of both difference in means and proportion of responders, all in the context of chronic pain.
Our study has some limitations. Fewer than half of the reports defined a term for the  (n 30) and few reports (n 16) justified theΔ = =
choice of the cut-off value; thus, for most articles, we could not determine whether the conclusions of the study were appropriate. In
addition, we studied only the use of the  in RCTs with 2 parallel arms. However, what constitutes a variation in clinically relevant painΔ
intensity is not likely to differ across trial designs. We did not find reports in all medical areas. However, we found no difference in the
value of the  across medical areas, so the values chosen for the  in trials from other fields may be close to those identified in our study.Δ Δ
Only 12 articles mentioned a hypothetical baseline pain state in both groups when detailing the sample size calculation; thus a sensibility
analysis of the variability of the delta depending on the baseline pain was performed using, when data were missing, the observed baseline
pain or, if not available, the control group pain during the study. However, the observed pain level could be different to the expected
baseline pain that was anticipated by the authors when choosing the value of the .Δ
Nevertheless, our systematic analysis of the literature on RCTs assessing analgesics for pain is a good reflection of the problems in
clinical trials assessing pain and in reporting results because we systematically selected all clinical trials for 2 recent years with very large
criteria of selection: pain as the primary outcome, pain assessed with a VAS or an NRS, and from all fields and all pathologic conditions
whatever the quality of reporting criteria.
This systematic review highlights the need for standardisation in the design and the reporting of results of trials assessing analgesic
interventions. We propose some recommendations for defining a clinically relevant difference in clinical trials assessing pain with a VAS
or an NRS ( ). Following Beaton s axes, the authors should first define the perspective of improvement they would like to apply the table 4 ’
 (group or individual), then they should decide if the  is an absolute difference (in mean or percentage) or a change within the sameΔ Δ
group. Finally, the value of the  would be chosen depending on the clinically pertinence of the change the authors would like toΔ
demonstrate, differentiating the smallest detectable change  that is often the standard error of measurement of the pain mean and do not“ ”
provide good indication of the importance of the observed change and the clinically important difference  (CID) or minimum clinically“ ” “
important difference  (MCID) or Minimum Clinical important improvement  (MCII). A lot of studies proposed values at the individual” “ ”
level for the CID with anchor-based approaches. At the group level, such important CID has not been proposed since it can only be
established on the broader context of the disease being treated, the currently available treatment and the overall risk-benefice ratio of the
treatment .[15 ]
In conclusion, this study showed that reporting clinical trial results of assessing analgesics for pain is very heterogeneous and
highlights the need for standardizing the definition of a clinically relevant difference in pain and cut-off values for such trials.
What is new ?
Great heterogeneity in the definition of what constitutes a clinically relevant difference in pain and confusion in these definitions may
be misleading in interpreting results.
Definition of clinically relevant difference in pain assessment
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A large variation of values used as the clinically relevant difference leads to difficulties in interpreting results.
Standardisations in the choice of the value and the term as the clinically relevant difference are advisable
The concept of clinically relevant difference in pain used in the sample size calculation should be the same as the primary outcome in
the result section.
In assessment of chronic pain, both absolute difference and proportion of responders should be presented in the results section.
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Figure 1
Flow-chart of the selection of articles of randomized controlled trials assessing analgesics for pain
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Figure 2
Plots representing the values of the clinically relevant difference in pain used in randomized controlled trials investigating analgesics
depending of the expected or observed baseline pain: absolute difference in means (mm) and difference in percentage change ( )%
Absolute difference: | |  * μfc −μfe Difference in percentage change: |( )/( )  ( )/( )|  ** μbe −μfe μbe − μbc −μfc μbc : Mean baseline score (at final visit)μbc 
in control group : Mean baseline score (at final visit) in experimental group μbe : Mean final score (at final visit) in control group μfc : Meanμfe 
final score (at final visit) in experimental group VAS visual analog scale = NRS numeric rating scale=
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Table 1
Characteristics of randomized controlled trials assessing analgesics for pain
Description Number Percentage
Type of trial
- Pharmacological 47 63.5
- Nonpharmacological 27 36.5
Primary outcome assessment
- VAS 1 56 75.7
- NRS 2 17 23.0
- Both 1 1.35
Type of pain
- Acute 44 59.5
- Chronic 30 40.5
Control group
- Placebo 40 54.1
- Other analgesic procedure 29 39.2
- No care 5 6.8
Sample size calculation reported 59 79.7
Sample size calculation data
- Alpha error not reported 8 13.6
- Power not reported 2 3.4
- not reportedΔ3 7 11.9
 - Control or treatment group assumptions incomplete or not reported4 40 67.8
 - At least one of the previous 47 79.7
1 Visual Analog Scale
2 Numeric Rating Scale
3 Definition of the clinically relevant difference used in the study
4 Expected mean value in the control or experimental groups or expected success rate in the control or experimental groups
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Table 2
Randomized controlled trials assessing analgesics for pain and inappropriate use of clinically relevant difference from references cited to justify values
Reference Trial
Collins and Chessell : The threshold for acceptable[23 ]
pain was 30 mm at the individual level.
Lipscomb et al. : Difference between groups was considered not clinically relevant because both group means were < 30 mm.[24 ]
Farrar et al. : The clinical improvement was 20 mm[18 ]
or 30  of improvement at the individual level.%
Berry and Petersen : The value of 30  was used at the group level in the sample size calculation.[25 ] %
Farrar et al. : The clinical improvement was 20 mm[18 ]
or 30  of improvement at the individual level.%
Qerama et al. : A 25  to 30  reduction from baseline was expected in the experimental group.[17 ] % %
Farrar et al. : The clinical improvement was 20 mm[26 ]
or 33  of improvement at the individual level.%
Suzuki et al. : The mean improvement in the experimental group was considered too small (< 20 mm) to be relevant.[27 ]
Felson et al. : An improvement of 20  significant at[28 ] %
the individual level.
Wong et al. : The authors concluded that the results for the experimental and placebo groups might be the same because the lower boundary of the[29 ]
confidence interval for the between-groups differences in means was < 20  of improvement.%
McQuay et al. : An significant improvement was a 30[30 ]
 decrease from baseline at the individual level.%
Langford et al. : For the sample size calculation, the expected difference between groups at endpoint was an absolute difference in means of 10 mm[31 ]
or a relative change of 38  at the group level. The authors did not specify which value they used in the sample size calculation.%
DeLoach et al. : Defined a threshold of imprecision[22 ]
at 20 mm at the individual level
Rattanachaiyanont et al. : Expected difference in means was 20 mm between groups.[21 ]
Table 3
Terms and values used to define the clinically relevant difference (absolute values are presented) in the 28 randomized controlled trials assessing analgesics for pain.
Study Terms used for the clinically relevantdifference
Value
Group level Individual level
Absolute difference1 
(mm)
Difference of percentage of
improvement ( )2 %
Threshold of improvement (mm3 
or )%
Threshold of acceptable pain4 
(mm)
( )Edelman et al. 2006 Clinical relevance 15
( )Hui et al. 2006 Clinical significance 20
( )Assis et al. 2006 Clinical significance change 20 <10 , 11 20 , 21 30 , >30% – % – % %
( )Suzuki et al. 2006 Clinically beneficial effect 10
( )Morgan et al. 2006 Clinically important difference 30
( )Pendleton et al. 2006 Clinically or substantively significant 10
( )Cepeda et al. 2005 Clinically meaningful decrease in pain 50%
( )Langford et al. 2006 Clinically meaningful difference 10 38
( )Ilfeld et al. 2005 Clinically relevant 40
( )Nikolajsen et al. 2006 Clinically relevant 20 40
( )Qerama et al. 2006 Clinically relevant 20 30 30%
( )Finnerup et al. 2005 Clinically relevant difference 15 33%
Clinically relevant pain 30
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( )van Wijck et al. 2006 
( )Lipscomb et al. 2006 Clinically significant 4
( )Turan et al. 2005 Clinically significant 15
( )Rog et al. 2005 Clinically significant 17.5 50%
( )Carvalho et al. 2006 Clinically significant difference 30
( )Ong et al. 2005 Clinically significant difference 20
( )Berry and Petersen 2005 Effect-size. Clinically significant 30
( )Chang et al. 2006 Minimal clinically significant difference 13
( )Wong et al. 2005 Minimum clinically important 20%
( )Hinman et al. 2007 Minimum clinically important difference 175
( )Chae et al. 2005 Minimum clinically significant difference 20mm
( )Casey et al. 2006 Minimum reduction in pain 20
(Rattanachaiyanont et al.
)2005 
Meaningful difference 20 40
( )Schenk et al. 2006 Relevant value for better pain 20 mm 30
( )Babcock et al. 2005 Significant improvement 30%
( )Turan et al. 2007 Significant reduction 25
: Mean baseline score (at the final visit of the trial) in control groupμbc 
: Mean baseline score (at the final visit of the trial) in experimental groupμbe 
: Mean final score (at the final visit of the trial) in control groupμfc 
: Mean final score (at the final visit of the trial) in experimental groupμfe 1 Absolute difference: | |μfc −μfe 2 Difference in percentage change: |( )/( )  ( )/( )|μbe −μfe μbe − μbc −μfc μbc 3 Threshold of improvement: definition of a threshold in change above which the patient is considered as improved and is classified as a responder. The threshold can be for an absolute change in
millimeters or a relative change in percentage.
4 Threshold of pain: threshold defining an acceptable level of pain above which a patient is considered painful (mm)
Table 4
Recommendations for reporting results of pain from randomised controlled trials
The relevant difference in pain used to calculate the sample size of a trial should be clinically relevant and realistic, and, if possible, should be supported by a reference addressing the same type of pain (acute or
chronic) and applied at the same level (group or individual).
The concept of clinically relevant difference in pain (i.e., axis according to Beaton) used for the sample size calculation should be the same as that used to report the main results in the results section.
In the assessment of chronic pain, both absolute difference and proportion of responders (IMMPACT and OMERACT recommendations) should be reported in the results section.
